This post is from a suggested group
The Global Angina Market: Addressing the Burden of Coronary Artery Disease, Advancing Anti-Anginal Pharmacotherapy, and Driving Demand for Revascularization Procedures in High-Risk Patients
The Angina Market is a massive and mature sector within cardiology, fundamentally driven by the high and increasing global prevalence of Coronary Artery Disease (CAD), which is the underlying cause of chest pain (angina) in millions of patients worldwide. The primary market catalyst is the relentless need for effective therapies to alleviate symptoms, improve patient quality of life, and prevent myocardial infarction (heart attack), necessitating a broad range of pharmacological and interventional strategies. The discussion must emphasize the sustained demand for established anti-anginal drugs, including nitrates, beta-blockers, and calcium channel blockers, which form the cornerstone of symptomatic management by improving the balance between myocardial oxygen supply and demand. Furthermore, the market is significantly propelled by the increasing procedural volume of percutaneous coronary intervention (PCI), often involving the…